-
Answers beyond results
The demands on your lab can be extraordinary. When you need expert assistance, it’s available from Arista Molecular whose vision is to pioneer advances in personalized medicine with NADiA technology.
Arista Molecular is a high complexity CLIA-certified laboratory which offers the NADiA ultrasensitive nucleic acid detection immunoassay platform. Arista Molecular will utilize its exclusive NADiA ProsVue assay to provide timely prognostic information that serves as an aid to clinicians in optimizing therapy for prostate cancer patients post-prostatectomy.
-
24 to 72 Hour Turnaround
Quick to Know
Every sample represents patients and physicians waiting for answers. All samples will have preliminary results reported within 24-to-72 hours of arrival at Arista Molecular.
Learn More -
Quality Assurance
Get it Right
We treat your samples with the level of care you would provide in your own lab. As part of standard operations, Arista Molecular runs blind spot-checks, ensuring that samples are being accessioned, stored, managed and reported correctly.
Learn More -
Consultation
Colleagues on Call
Pathologist-to-pathologist consulting is available by phone 24/7/365. Our pathologists are experienced in anatomical, clinical and molecular pathology, and are well prepared to consult on difficult cases, offer a point of view on triaging the testing process, or confer with your physicians. With the backing of Arista Molecular, you have the time and the resources to serve as a greater source of expertise within your institution.
Learn More -
Easy to read. Easy to pass on.
Right to Results
Arista Molecular results reports are designed to deliver key information quickly and clearly. With an eye towards your customer—the physician—the results report prioritizes essential information in a crisp, easy-to-read format.
Learn More
Introducing NADiA ProsVue
ProsVue is the first NADiA assay FDA cleared as a Prognostic Prostate Cancer Test.
NADiA ProsVue is expected to reduce unnecessary treatment of certain post-prostatectomy men thus reducing the morbidity and costs associated with adjuvant treatment such as radiation therapy.
ProsVue Receives FDA (510k) Clearance
IRIS International Receives FDA (510k) Clearance for Its NADiA ProsVue Prognostic Cancer Test.
NADiA ProsVue slope is indicated for use as a prognostic marker in conjunction with clinical evaluation as an aid in identifying those patients at reduced risk for recurrence of prostate cancer for the eight-year period following prostatectomy. Learn more.